AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01878786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
Study NCT03757130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching to AMG 598 administered by subcutaneous injection
Study NCT03757130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.
Study NCT03757130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.
Study NCT00475865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration
Study NCT00475865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for teriflunomide)
Description: Film-coated tablet~Oral administration
Study NCT00475865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glatiramer Acetate (GA)
Description: Solution in prefilled syringe for subcutaneous injection
Study NCT00475865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (GA)
Description: Solution in prefilled syringe for subcutaneous injection
Study NCT02320851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SVD-tailored Integrative Psychotherapy (IPT)
Description: (see description of corresponding study arm)
Study NCT02320851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help group (SHG)
Description: (see description of corresponding study arm)
Study NCT01521910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low protein diet
Description: An iso-caloric low protein diet of 0.6 g/kg/day was prescribed during the whole study duration.~The same dietician gave nutritional advices at least every three months during the whole study period. Patients were also seen by the same doctor during each visit for the whole study period.~Supplementation of Calcium of 500mg/day.~Urine albumin losses >= 2 g/day wre replaced by increasing dietary protein on a gram-for-gram basis, only if the patient was compliant with the prescribed low-protein diet.
Study NCT01521910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: normal protein diet
Description: The patients pre-study diet during the whole study period~Patients were also seen by the same doctor during each visit for the whole study period.
Study NCT03931915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 40 mg tablets + Leuprorelin acetate placebo injection
Study NCT03931915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin acetate
Description: TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection
Study NCT03043677 — intervention group
Intervention type: BIOLOGICAL
Intervention: Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab
Description: Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.~Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems.
Study NCT01900977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Universal Testing with immediate ART
Description: • Combination prevention package including:~o House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units
Study NCT01900977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Universal Testing with ART eligibility according to National Guidelines
Description: Combination prevention package including:~House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units.
Study NCT01900977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Study NCT01903889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinic based intervention
Description: counseling C\&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
Study NCT01903889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinic and community based intervention
Description: basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services
Study NCT03099148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Formulation (R)
Description: Administered PO
Study NCT03099148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641 (T1)
Description: 20 mg PO
Study NCT03099148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641 (T2)
Description: 20 mg PO
Study NCT03455439 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: As prescribed by the treating physician
Study NCT02338934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Cinacalcet with Vitamin D analogue
Description: Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal \<2.4 mmol/L - Start Cinacalcet 25mg OD \& Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if >2.54 mmol/L - Start Cinacalcet 25mg OD \& Maintain active Vit D dose. Then they will go to maintenance phase.
Study NCT01576328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: Single intravenous infusion of MPCs Dose 1
Study NCT01576328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: Single intravenous infusion of MPCs Dose 2
Study NCT01576328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: Single intravenous infusion of MPCs Dose 3
Study NCT02953665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg
Study NCT02953665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg
Study NCT04366557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy, exercises and education program
Description: a six week body posture therapy consisted of manual therapy (once per week) and home exercises; education about pelvic floor
Study NCT04366557 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education program
Description: education about pelvic floor
Study NCT03033953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Native whey
Study NCT03033953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk
Study NCT03033953 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strength training
Study NCT03033953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Study NCT02725242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide (400μg/d)
Description: After the patients who have all criteria, they will be randomization to take Budesonide (200 ug) twice daily
Study NCT02071888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Glutaminase inhibitor
Study NCT01878786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF/MPA)
Description: Control Drug
Study NCT02071888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839 and low dose dexamethasone
Description: CB-839 and low dose dexamethasone
Study NCT02071888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839, pomalidomide, and low dose dexamethasone
Description: CB-839, pomalidomide, and low dose dexamethasone
Study NCT00907985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo will be provided.
Study NCT02773511 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical treatment
Description: Closed reduction and Kirschner wire fixation
Study NCT00907985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vofopitant
Description: Vofopitant (GR205171) will be provided as 5 milligram single dose capsule administered orally. It will be available as swedish orange, size 0 capsules.
Study NCT00907985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine will be provided as 25 milligrams or 100 milligrams single dose dispersible tablet administered orally.
Study NCT04511793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Synchromed II pump
Description: The pump will be placed during surgery and the pump will be filled with a combination of floxuridine (FUDR), dexamethasone, heparin, and saline.
Study NCT03159481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care + Health Promotion Intervention
Description: Telephone sessions for approximately 5-6 weeks to enhance empowerment and skills for managing medication adherence.
Study NCT00888095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation
Description: electrode implantation in either STN or cZI
Study NCT02742987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 90 mg twice daily
Study NCT02742987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 150 mg once daily
Study NCT02742987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical therapy
Description: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
Study NCT00847457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercises completed three to four times per week for 20 to 30 minutes per session
Study NCT00847457 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Easy to moderate stretching routines completed three times per week, with a new set of routines given each week
Study NCT02221375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHT low
Study NCT02221375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHT medium
Study NCT02221375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHT high
Study NCT02221375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 XX low
Study NCT02221375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 XX medium 1
Study NCT02221375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 XX medium 2
Study NCT02221375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 XX high
Study NCT02221375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Study NCT03839212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOLA Component 1
Description: At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
Study NCT03839212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOLA Component 2
Description: A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
Study NCT03839212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOLA Component 3
Description: A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
Study NCT03839212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOLA Component 4
Description: One booster walking session twice a month for three months post intervention for reinforcement.
Study NCT00452829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid and inositol
Description: Folic Acid and inositol
Study NCT00452829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid and placebo
Description: Folic acid and placebo
Study NCT03384979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopamidol
Description: Contrast agent will be adrministered intravenously using total body weight or lean body weight, calculated with bioelectrical impedance analysis balance.
Study NCT03384979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iopamidol
Description: Contrast agent will be adrministered intravenously using total body weight or lean body weight, calculated with bioelectrical impedance analysis balance.
Study NCT01607996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: Epidural will be performed using carbostesin (0.1%), fentanyl (2 microg/ml) administered continuously at a rate of 6 to 15 ml/hour
Study NCT01607996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled intravenous analgesia
Description: Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour
Study NCT02768636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: Omega-3 or Fish oil (1000 mg.) is taken for one capsule a day in 30 days duration. Heart rate variability is tested before at starting day and later follow up it again in the next 30 days appointment.
Study NCT00875966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC
Study NCT00875966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer
Description: Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
Study NCT02677506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supraclavicular
Description: Brachial plexus block with supraclavicular approach
Study NCT02677506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular
Description: Brachial plexus block with infraclavicular approach
Study NCT01327924 — intervention group
Intervention type: DRUG
Intervention: Norditropin NordiFlex®
Description: Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
Study NCT03000413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Active treatment
Study NCT03000413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT03703661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle-Aspirated Negative Pressure Dressing
Description: dressing consisting of Needle-Aspirated Negative Pressure dressing with gauze and adhesive/occlusive dressing, placed over wound after primary closure
Study NCT03703661 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: dressing consisting of gauze and adhesive/occlusive dressing, placed over wound after primary closure
Study NCT00601510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00601510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00601510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT02557633 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL 10200
Study NCT02557633 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL 18200
Study NCT02557633 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03089489 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lung biomarkers in organ donor for PGD in lung recipient
Description: Lung biopsies in organ donor before and after cold ischemia
Study NCT03459794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: 150 mcg/kg ivermectin, by mouth.
Study NCT03459794 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral placebo will be administered, once
Study NCT02364999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-Pfizer
Description: Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.
Study NCT02364999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab-EU
Description: bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.
Study NCT02364999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
Study NCT02364999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
Study NCT02364999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.
Study NCT02364999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.
Study NCT00606931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereo Navigator Accessory to PEM Flex PET Scanner
Description: For patients with suspicious breast abnormalities seen on high resolution PET image, the patients will be biopsied using commercial vacuum biopsy devices (pre-validated to work with Stereo Navigator) using Naviscan's Stereo Navigator (interventional device) for PET image guidance.
Study NCT03729128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan and memantine (DM+MM)
Description: Patients of Amphetamine-type stimulants use disorder (ATSUD) will take dextromethorphan 30 mg/day and memantine 5 mg/day combination (DM+MM) daily for 12 weeks.
Study NCT03729128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients of Amphetamine-type stimulants use disorder (ATSUD) will take placebos daily for 12 weeks.
Study NCT01935622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 1 tablet every 12 hours for 14 days
Study NCT01935622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 1 tablet every 12 hours for 14 days
Study NCT01676428 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The investigational treatment will be prescribed as a 2-tiered dose scheduled dependant on target size.~For lesions \<5cm, a single fraction of 26Gy will be prescribed. For lesions ≥5cm a fractionated course of 14Gy by 3 fractions will be prescribed, delivered at least 48 hours apart.
Study NCT03436095 — intervention group
Intervention type: OTHER
Intervention: bundle measures
Description: Implementation of bundle measures to improve the successful rate of weaning ventilator